



Correction to: Regdanvimab: First Approval

Yahiya Y. Syed¹

Published online: 16 November 2021
© Springer Nature Switzerland AG 2021

Correction to: **Drugs (2021)**

<https://doi.org/10.1007/s40265-021-01626-7>

Authorship and Conflict of Interest statement, first sentence, which currently reads:

During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article.

Should read:

During the peer review process, Celltrion Healthcare Co., Ltd, was offered an opportunity to comment on the article.

This is to clarify that Celltrion Healthcare Co., Ltd and not Celltrion Inc., the manufacturer of the agent reviewed, was approached for the review process.

The original article has been updated.

The original article can be found online at <https://doi.org/10.1007/s40265-021-01626-7>.

✉ Yahiya Y. Syed
dru@adis.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand